All In MedTech

Device Trial Radar · NCT07920484

A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin.

A Prospective, Multicenter, Post-Market Clinical Study Collecting Real-World Data of the VCFix Spinal System in Stand-Alone Configuration for Vertebral Augmentation (EXPAND-US)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 4, 2026

Primary completion

Jul 21, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Amber Implants B.V.Not on our public-company list
Sponsor type
Industry
First posted
Nov 5, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice. Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use. The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility. The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.

Conditions

  • Vertebra Compression Fracture

Interventions

  • VCFix Spinal System in stand-alone configurationDevice

    The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of serious adverse events (SAEs) related to the device and/or investigational procedure (safety)Time frame: 1 month
  2. Vertebral fracture-related pain as assessed by the Numeric Pain Rating Scale (NPRS)Time frame: 6 months
  3. Functional disability, measured by the Oswestry disability index (ODI)Time frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Montefiore Medical Center

    New York, New York · Recruiting

  • University of Oklahoma Health Campus

    Oklahoma City, Oklahoma · Not yet recruiting

  • Rothman Orthopaedics

    Philadelphia, Pennsylvania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.